Please select the option that best describes you:
How would manage a patient with primary mediastinal NSGCT who has radiographic response but rising AFP while receiving VIP?
Do you routinely check tumor markers between cycles when managing NSGCT?
Answer from: Medical Oncologist at Academic Institution
Patients with PMNSGCT are poor risk disease regardless of the size of the primary or amplitude of tumor markers hCG and AFP. For patients getting any cisplatin combination chemo, including testis primary, we always check tumor markers on day 1 of each course. In the patient in question, a rising mar...
Sign in or Register to read more